CFS Investment Advisory Services LLC Invests $1.13 Million in Becton, Dickinson and Company (NYSE:BDX)

CFS Investment Advisory Services LLC bought a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 4,690 shares of the medical instruments supplier’s stock, valued at approximately $1,131,000.

Several other institutional investors have also added to or reduced their stakes in the business. Raymond James Trust N.A. raised its stake in shares of Becton, Dickinson and Company by 1.8% in the third quarter. Raymond James Trust N.A. now owns 12,891 shares of the medical instruments supplier’s stock worth $3,108,000 after buying an additional 231 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after acquiring an additional 1,317,723 shares in the last quarter. Smithfield Trust Co raised its stake in Becton, Dickinson and Company by 2.8% during the 3rd quarter. Smithfield Trust Co now owns 3,946 shares of the medical instruments supplier’s stock worth $945,000 after acquiring an additional 108 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after acquiring an additional 460,440 shares during the period. Finally, John G Ullman & Associates Inc. purchased a new position in Becton, Dickinson and Company during the third quarter valued at approximately $270,000. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on BDX shares. Raymond James reduced their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. Stifel Nicolaus raised their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a report on Friday, July 26th. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Trading Down 0.6 %

Shares of Becton, Dickinson and Company stock opened at $224.00 on Friday. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $249.89. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The business has a 50-day moving average price of $235.15 and a 200-day moving average price of $234.56. The firm has a market cap of $64.74 billion, a price-to-earnings ratio of 37.71, a PEG ratio of 1.66 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the business posted $3.42 EPS. Equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be paid a dividend of $1.04 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio is presently 63.97%.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.